Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era”

Jim Cramer's negative commentary on ImmunityBio labels the stock as part of the 'Magical Thinking Era,' suggesting it may be overvalued and driven by hype rather than solid fundamentals, potentially leading to increased volatility or selling pressure in the short term. While Cramer's opinions can influence retail investors, their impact is often limited as markets may have already discounted such views. Overall, this highlights the risks in biotech stocks amid broader market sentiments, but it does not constitute a major catalyst for price changes.